Catalent (NYSE:CTLT) Announces Quarterly Earnings Results

Catalent (NYSE:CTLTGet Free Report) issued its earnings results on Friday. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22), MarketWatch Earnings reports. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the prior year, the business earned $0.62 EPS. The business’s quarterly revenue was down 10.2% on a year-over-year basis.

Catalent Stock Up 0.3 %

CTLT opened at $56.71 on Monday. Catalent has a 1-year low of $31.45 and a 1-year high of $74.49. The company has a quick ratio of 1.73, a current ratio of 2.47 and a debt-to-equity ratio of 1.34. The company has a fifty day moving average price of $47.00 and a two-hundred day moving average price of $44.77.

Analysts Set New Price Targets

A number of equities analysts have recently commented on CTLT shares. Stephens reiterated an “equal weight” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, February 6th. UBS Group reiterated a “neutral” rating and set a $63.50 price target (up previously from $58.00) on shares of Catalent in a report on Tuesday, February 6th. William Blair reiterated a “market perform” rating on shares of Catalent in a report on Tuesday, November 14th. Robert W. Baird upgraded shares of Catalent from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $45.00 to $53.00 in a report on Thursday, November 16th. Finally, Wells Fargo & Company cut their price target on shares of Catalent from $50.00 to $42.00 and set an “equal weight” rating on the stock in a report on Thursday, November 16th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $52.46.

View Our Latest Research Report on Catalent

Institutional Investors Weigh In On Catalent

Several hedge funds and other institutional investors have recently bought and sold shares of CTLT. KB Financial Partners LLC acquired a new position in shares of Catalent during the first quarter valued at about $30,000. Jefferies Financial Group Inc. acquired a new position in shares of Catalent during the fourth quarter valued at about $61,000. Covestor Ltd grew its holdings in shares of Catalent by 84.9% during the first quarter. Covestor Ltd now owns 562 shares of the company’s stock valued at $62,000 after buying an additional 258 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in shares of Catalent during the third quarter valued at about $163,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Catalent by 112.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $189,000 after buying an additional 2,313 shares during the last quarter.

About Catalent

(Get Free Report)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

Further Reading

Earnings History for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.